{"filing":{"accession_number":"0001213900-26-096442","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"ea0304201-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026096442/ea0304201-6k_canfite.htm"},"events":[{"id":31142,"run_id":28567,"accession_number":"0001213900-26-096442","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces a positive interim development in Can-Fite's pivotal Phase III trial of Namodenoson for hepatocellular carcinoma—specifically, longer-than-anticipated overall survival in the blinded study population and the company's decision to advance the timing of the planned interim analysis. While the company emphasizes that no treatment efficacy conclusions can yet be drawn (the study remains blinded), the announcement of improved survival metrics and acceleration of interim analysis represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the drug candidate's development trajectory and commercial prospects. This is not a discrete earnings release, M\u0026A event, or executive change, but rather a material clinical-development milestone.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":33946,"accession_number":"0001213900-26-096442","item_number":"EX-99.1","item_title":"ea030420101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a positive interim development in Can-Fite's pivotal Phase III trial of Namodenoson for hepatocellular carcinoma—specifically, longer-than-anticipated overall survival in the blinded study population and the company's decision to advance the timing of the planned interim analysis. While the company emphasizes that no treatment efficacy conclusions can yet be drawn (the study remains blinded), the announcement of improved survival metrics and acceleration of interim analysis represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the drug candidate's development trajectory and commercial prospects. This is not a discrete earnings release, M\u0026A event, or executive change, but rather a material clinical-development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:04:39.429447+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33946,"accession_number":"0001213900-26-096442","item_number":"EX-99.1","item_title":"ea030420101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a positive interim development in Can-Fite's pivotal Phase III trial of Namodenoson for hepatocellular carcinoma—specifically, longer-than-anticipated overall survival in the blinded study population and the company's decision to advance the timing of the planned interim analysis. While the company emphasizes that no treatment efficacy conclusions can yet be drawn (the study remains blinded), the announcement of improved survival metrics and acceleration of interim analysis represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the drug candidate's development trajectory and commercial prospects. This is not a discrete earnings release, M\u0026A event, or executive change, but rather a material clinical-development milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T11:04:39.429447+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-02"}]}